NEOPHARM REPORTS CINTREDEKIN BESUDOTOX DATA

A A

NeoPharm has reported that cintredekin besudotox continues to show evidence of prolonged overall survival in patients with recurrent glioblastoma multiforme.

The overall median survival for these patients was 44.0 weeks, with survival increasing to 53.6 weeks for the 26 patients with two or more optimally placed catheters.